SAUSALITO, Calif., Jan. 24, 2012 /PRNewswire/ -- Sanovas CEO Larry Gerrans will participate in a panel titled "Fundraising in Troubled Times" as part of BayBio's Life Sciences Series on Thursday, Jan. 26 at 8 a.m. in Palo Alto. The event will take place at the Silicon Valley offices of DLA Piper.
Gerrans will speak about alternative approaches to funding and the emerging trends and opportunities in business financing, including the proposed legislative changes to the laws that currently govern the securities industry. Gerrans will offer insights into how emerging companies can leverage private investment sources, such as Individual Retirement Accounts, and how social media is revolutionizing investment financing worldwide.
"The current environment in the capital markets has forced individuals and businesses to think and act in new ways," Gerrans said. "There is an exciting socio-economic recovery in the making. Social networking and independent-minded people are driving the new age of capitalism. Entrepreneurs can, and should, look to individuals to find their seed capital and to share their profits. The new paradigm is communal wealth."
A pioneer in the field of minimally invasive surgery, Gerrans served in executive-level positions at Stryker Corp., Smith & Nephew Corp. and DePuy Orthopedics (Johnson & Johnson), before co-founding Sanovas. Based in Sausalito, Calif., Sanovas is a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases.
The panel presentation will also feature Jerry Iwata, vice president of Wells Fargo Bank; Bruce W. Jennett, partner and co-chair, Global Life Sciences Sector DLA Piper; Michael Power, PhD, general partner, Soffinova Ventures; and Kim Tsuchimoto, chief financial officer, treasurer and secretary of Raptor Pharmaceutical Corp. BayBio is the Northern California association serving the life science industry.
Sanovas, Inc., based in Sausalito, Calif., is a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases. Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body, enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. The company plans to commercialize its technology platform, which will initially address the unmet needs in lung cancer and pulmonary disease, in 2012. Privately held Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 25 multi-national patents pending.
For information, go to http://www.Sanovas.com
SOURCE Sanovas, Inc.